

10/561884

Attorney Docket No. Le A 36 769

IAP20 Rec'd PCT/PTO 23 DEC 2005 ^{PATENT}

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Flessner, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP04/006682

Title: AMIDE-SUBSTITUTED 1,2,4-TRIAZIN-5(2H)-ONES FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY
37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO].


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Barbara A. Shimer
Reg. No.: 29,862
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-2786
Facsimile: (203) 812-6459

